{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(8)"],"submitter":["Fumagalli S"],"funding":["Menarini Group"],"pubmed_abstract":["Aims
Ranolazine (Ran) is an anti-anginal drug inhibiting late sodium current, an action possibly hindering arrhythmias onset. Indeed, some evidence supports the anti-arrhythmic effects of Ran. The aim of this study, which evaluated Italian patients with chronic coronary syndrome (CCS), was to investigate whether Ran, as an add-on therapy, was associated with a lower incidence of atrial fibrillation (AF) compared with no-Ran prescription (No-Ran).Methods and results
The original population (N = 6.1 million) derived from the databases of the Italian National Health System; information concerned hospitalizations with the related diagnoses, drug therapy, follow-up clinical events and visits. Patients hospitalized between 2011 and 2020 for any cause and discharged with an ICD-9-"],"journal":["European heart journal. Cardiovascular pharmacotherapy"],"pagination":["674-681"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12705168"],"repository":["biostudies-literature"],"pubmed_title":["Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug."],"pmcid":["PMC12705168"],"pubmed_authors":["Cerbai E","Fumagalli S","Spanalatte G","Fumagalli C","Santamaria E","Tariello A","Mazzoni S","Cagnoni C","Dovizio M","Marchionni N","Degli Esposti L"],"additional_accession":[]},"is_claimable":false,"name":"Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug.","description":"Aims
Ranolazine (Ran) is an anti-anginal drug inhibiting late sodium current, an action possibly hindering arrhythmias onset. Indeed, some evidence supports the anti-arrhythmic effects of Ran. The aim of this study, which evaluated Italian patients with chronic coronary syndrome (CCS), was to investigate whether Ran, as an add-on therapy, was associated with a lower incidence of atrial fibrillation (AF) compared with no-Ran prescription (No-Ran).Methods and results
The original population (N = 6.1 million) derived from the databases of the Italian National Health System; information concerned hospitalizations with the related diagnoses, drug therapy, follow-up clinical events and visits. Patients hospitalized between 2011 and 2020 for any cause and discharged with an ICD-9-","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T03:46:12.171Z","creation":"2026-05-25T03:11:25.895Z"},"accession":"S-EPMC12705168","cross_references":{"pubmed":["41026986"],"doi":["10.1093/ehjcvp/pvaf074"]}}